

# special articles **Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents**

Lucas Moreno, MD, PhD<sup>1</sup>; Steven G. DuBois, MD, MS<sup>2</sup>; Julia Glade Bender, MD<sup>3</sup>; Audrey Mauguen, PhD<sup>3</sup>; Nick Bird, MSc<sup>4</sup>; Vickie Buenger, PhD<sup>5</sup>; Michela Casanova, MD<sup>6</sup>; François Doz, MD<sup>7,8</sup>; Elizabeth Fox, MD<sup>9</sup>; Lia Gore, MD<sup>10,11</sup>; Douglas S. Hawkins, MD<sup>12,13</sup>; Shai Izraeli, MD<sup>14,15</sup>; David T.W. Jones, PhD<sup>16,19</sup>; Pamela R. Kearns, MB ChB, PhD<sup>20,21</sup>; Jan J. Molenaar, MD, PhD<sup>22,23</sup>; Karsten Nysom, MD, PhD<sup>24</sup>; Stefan Pfister, MD<sup>16,17,18</sup>; Gregory Reaman, MD<sup>25</sup>; Malcolm Smith, MD, PhD<sup>26</sup>; Brenda Weigel, MD, MSc<sup>27</sup>; Gilles Vassal, MD, PhD<sup>28,29,30</sup>; Christian Michel Zwaan, MD, PhD<sup>22,31</sup>; Xavier Paoletti, PhD<sup>32</sup>; Alexia Iasonos, PhD<sup>3</sup>; and Andrew D.J. Pearson, MBBS, MD, DCH<sup>28,29</sup>

abstract

**PURPOSE** There is an increasing need to evaluate innovative drugs for childhood cancer using combination strategies. Strong biological rationale and clinical experience suggest that multiple agents will be more efficacious than monotherapy for most diseases and may overcome resistance mechanisms and increase synergy. The process to evaluate these combination trials needs to maximize efficiency and should be agreed by all stakeholders.

**METHODS** After a review of existing combination trial methodologies, regulatory requirements, and current results, a consensus among stakeholders was achieved.

**RESULTS** Combinations of anticancer therapies should be developed on the basis of mechanism of action and robust preclinical evaluation, and may include data from adult clinical trials. The general principle for combination early-phase studies is that, when possible, clinical trials should be dose- and schedule-confirmatory rather than dose-exploratory, and every effort should be made to optimize doses early. Efficient early-phase combination trials should be seamless, including dose confirmation and randomized expansion. Dose evaluation designs for combinations depend on the extent of previous knowledge. If not previously evaluated, limited evaluation of monotherapy should be included in the same clinical trial as the combination. Randomized evaluation of a new agent plus standard therapy versus standard therapy is the most effective approach to isolate the effect and toxicity of the novel agent. Platform trials may be valuable in the evaluation of combination studies. Patient advocates and regulators should be engaged with investigators early in a proposed clinical development pathway and trial design must consider regulatory requirements.

**CONCLUSION** An optimized, agreed approach to the design and evaluation of early-phase pediatric combination trials will accelerate drug development and benefit all stakeholders, most importantly children and adolescents with cancer.

**J Clin Oncol 41:3408-3422. © 2023 by American Society of Clinical Oncology**

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License 

## INTRODUCTION

There is an urgent need to develop new therapies for children and adolescents with cancer, both to improve outcome for poor prognosis malignancies<sup>1</sup> and to reduce acute and long-term adverse effects of current treatments.<sup>2,3</sup> Biological rationale and published experience indicate that combination approaches, particularly those that use agents with robust single-agent activity,<sup>4-6</sup> will be more efficacious than the same agents used alone. Therefore, there is an increasing need to evaluate innovative drugs for childhood cancer using combinatorial strategies. The adult drug development landscape has radically evolved over the past decade, moving away from a traditional approach to seamless-design, phase I/II trials for single agents.<sup>7</sup> Seamless trials can address multiple objectives under the heading of early-phase investigation and allow for rapid completion.

Consensus articles have described the conduct of early-phase trials in children to bring beneficial innovative agents more rapidly to the clinic.<sup>8,9</sup> With the increasing evaluation of agents in combination, there is a need for a consensus to combination early-phase trials. New combinations may be developed with existing standard-of-care chemotherapy regimens or with other new agents (novel-novel combinations). The goal should be to evaluate drug combinations rapidly and efficiently, without compromising identification of safety signals or assuming unnecessary risks of toxicity. Ideally, this should require the smallest number of patients to enroll to determine safe dose(s) and schedule, identify early signals of activity, and reach a go/no-go decision in a tumor or target-specific population.

In addition to efficient trial designs, three changes are needed to accelerate evaluation of innovative medicines in children. The first change requires that the

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on February 7, 2023 and published at [ascopubs.org/journal/jco](https://ascopubs.org/journal/jco) on April 4, 2023; DOI <https://doi.org/10.1200/JCO.22.02430>

## CONTEXT

### Key Objective

To achieve an international consensus among stakeholders on the process to design and deliver early-phase combination trials in children and adolescents with cancer.

### Knowledge Generated

An efficient, effective approach on the basis of mechanism of action and robust preclinical evaluation is recommended to evaluate new combinations of anticancer agents and identify the efficacy and toxicity of each novel agent. The very early involvement of patient advocates and regulators in a proposed clinical development pathway and trial design is crucial.

### Relevance (S. Bhatia)

This paper provides general guidance to accelerate the availability of optimized treatments for children and adolescents with cancer.\*

\*Relevance section written by JCO Associate Editor Smita Bhatia, MD, MPH, FASCO.

development of anticancer medicines and combinations for children be based on the biology of childhood cancers and the mechanism of action of the drug(s) investigated rather than the adult indication.<sup>10,11</sup> The second requires that new drugs with high potential for benefit be assessed quickly and early in the context of the development in adults. A third improvement is expanding in vivo preclinical testing using genomically characterized pediatric models to provide the strongest possible data set for prioritizing specific combinations among the multitude of potential combinations that could be evaluated clinically.<sup>12</sup> These changes can reduce the unacceptable delay (median 6.5 years) from the initiation of first-in-human trials to first-in-child trials.<sup>13</sup> Legislation in Europe,<sup>14,15</sup> and more recently in the United States,<sup>16</sup> prioritizes science-driven, patient-oriented, pediatric oncology drug development over adult-indication approaches. These regulatory advances, together with the international multi-stakeholder organization ACCELERATE, promote children having greater access to innovative, safe, and effective treatments.<sup>17,18</sup>

Early engagement of regulators in the clinical development of agents for pediatric cancers is critical. Trial design needs to consider regulatory requirements (pediatric investigation plan and initial pediatric study plans) along a full clinical development pathway including early- and late-phase combination trials for novel agents, and for all drugs included in the combination. By aligning scientific, regulatory, and payer (eg, European health technology assessment bodies) requirements from the inception of a clinical trial, the fewest number of patients will need to be enrolled to obtain sufficient evidence for scientific and regulatory purposes.<sup>18</sup> Similarly, involving patient advocates early and throughout discussions is important for both pragmatic and principled reasons.<sup>19</sup> Doing so ensures the patient voice is heard and that specific unmet needs are accounted for in all phases of pediatric oncology drug development.<sup>18</sup>

Herein, we report a consensus opinion among invested stakeholders and discuss salient points that should be considered in the development of early-phase combination trials for pediatric oncology, presenting best practices whenever possible.

## SUMMARY OF RECOMMENDED PRACTICE FOR GENERAL PEDIATRIC ONCOLOGY EARLY-PHASE TRIALS

Prior position statements have strongly advocated that the pediatric clinical evaluation of a new anticancer drug follows an early-phase seamless trial design rather than individual phase I and II trials.<sup>10,20-22</sup> An early-phase clinical trial has two components: (1) a dose-finding or dose-confirmation phase and (2) expansion cohort(s) (Table 1) in which optimal dosing, toxicity profile, pharmacokinetic (PK) parameters, pharmacodynamic (PD) effects, and early signals of antitumor activity are obtained. The therapeutic agent is then transitioned to late-stage trials to determine antitumor efficacy and comparison with current standard(s) of care. Avoiding the distinction between different phases of development can reduce the numbers of exposed patients and as well limit cost, resource requirements, trial development timelines, and trial duration. Monotherapy or combination platform trials<sup>23</sup> with several parallel arms<sup>24-28</sup> are examples of potential frameworks with many advantages (Table 2).

In practice, no differences have been observed in the PK of cytotoxic drugs between patients age 5-11 and 11-16 years, or between 12-16 and 16-21 years.<sup>29-33</sup> Furthermore, the median age of enrollment was 12 years or younger in 15 of 20 recent Innovative Therapies for Children with Cancer (ITCC)-published phase I trials (F. Bautista, personal communication, January 2023). Therefore, to expedite dose-finding for pediatric patients, age-specific cohorts for the majority of pediatric patients are discouraged. Additional PK/PD data can be collected in infants age 2 years and younger, who are anticipated to have different metabolism, using dedicated PK/PD expansion cohorts at the recommended phase II dose (RP2D) and in later-phase studies.

**TABLE 1.** General Principles of Pediatric Early-Phase Clinical Trials

Component	Recommendations	Rationale
Dose-finding or dose-confirmation phase	Starting dose: If a drug has neither serious dose-related toxicities nor a narrow therapeutic index: Adult RP2D (if known) corrected for patient size (BSA or weight) Objectives: Confirm toxicity profile, RP2D, and preliminary PK parameters with minimal dose ranging Extrapolation from data in adults should be considered, when possible <sup>22</sup>	Pediatric RP2D of most molecularly targeted drugs range between 90% and 130% of the BSA-adjusted RP2D for adults and, in the absence of DLT, is often based on PKs <sup>20,21</sup>
Expansion cohorts	Early signals of antitumor activity Additional PK, PD, and safety data including young children and infants Opportunity to evaluate a child-friendly oral formulation that was not available at the start of trial	Generate activity data to inform potential late-phase trials in target population of interest

Abbreviations: BSA, body surface area; DLT, dose-limiting toxicity; PD, pharmacodynamic; PK, pharmacokinetic; RP2D, recommended phase II dose.

Early-phase trials should also avoid defining a lower age limit for inclusion, unless biologically justified. To this end, developing age-appropriate formulations is critical. However, this development should not delay the start of the first-in-child trial. Rather, trials should begin using tablets or capsules, feasible to reliably deliver a pediatric dose with adult formulations. When a child-friendly formulation becomes available with bioequivalence data, this should be used and PK data for the new formulation collected subsequently.

A mechanism of action, tumor-agnostic development approach provides more opportunities for rapid and focused pediatric and adult drug development, if the relevant biomarker is also age-agnostic.<sup>34,35</sup>

## CONSIDERATIONS FOR PEDIATRIC COMBINATION TRIALS

### General Principles

Early-phase combination trials, like monotherapy trials, should be seamless and encompass both a dose-finding/confirmation and an activity evaluation phase. Different approaches are required for safely combining agents on the basis of prior clinical experience with the agent or agents-in-class.

**TABLE 2.** Advantages of Platform Trials for Clinical Drug Development in Children With Cancer

Advantage
Share molecular profiling across arms <sup>a</sup>
Standardize data management and biological samples
Accelerate the introduction of new combination arms
Facilitate joint analyses of two arms with a common investigational agent and different backbone
Facilitate joint analyses of specific tumor types
Facilitate translational research across cohorts
Maximize the probability that a child enters one of the arms, as prevalence of molecular abnormalities is often low
Improve operational efficiency rather than opening multiple individual trials

<sup>a</sup>It is frequently mandatory to have molecular screening of subjects when partial or complete enrichment is required to evaluate activity.

Combinations may contain agents previously studied in children as monotherapy, or those for which there are only adult data. When agents are combined, new toxicities can occur that are not present when agents are administered individually, and overlapping toxicity is possible. For combinations of a novel drug with standard-of-care chemotherapy, scenarios depend on whether the pediatric PK and safety profile of the new drugs is known, and if overlapping toxicities or PK interactions are expected. Novel-novel combinations are indicated when there is a strong biological rationale with robust preclinical data and are particularly compelling if early proof-of-principle clinical data exist.<sup>36</sup> For novel-novel combinations, scenarios depend on whether the products have (1) known pediatric PK and safety profiles; (2) known adult PK and safety profiles; (3) metabolism that is expected to contribute to PK interactions; and (4) observed or expected interactions or overlapping toxicities (Table 3, Fig 1).

Parents enroll their children on early-phase clinical trials in the hope that participation will directly benefit them.<sup>37,38</sup> Although the goal of a trial is to address a scientific question, therapeutic intent (ie, the potential for patient benefit, balanced against potential or real short- and long-term toxicity) should guide trial design considerations. This means conducting appropriate patient selection during dose-finding to maximize chances of benefit, avoiding subtherapeutic doses, minimizing single-agent evaluations, except when necessary, and rapidly assessing agent efficacy. To limit the number of patients who receive a dose less than a potentially beneficial treatment, intrasubject dose escalation should be considered. Maximum dose escalation may also not be required if the dose used in adults (if any) provides evidence of biological activity and is supported by PK. A unique aspect of combination trials is to demonstrate signals of improved activity over either monotherapy or standard of care. Randomization is of value and follows the European Medicine Agency (EMA) guidelines for combination development.<sup>36</sup>

**TABLE 3.** Clinical Scenarios and Proposed Design and Starting Dose Strategies

Clinical Scenario	Proposed Strategies (Design/Starting Dose)	
	PK, RP2D, and Safety Profile	Overlapping Toxicities or Drug-Drug Interaction
Novel Drug Added to Standard of Care (2 or 3 drugs) and New Drug. Only One Novel Drug Escalated		
	Not Expected	Expected
Known in children	Dose confirmation/pediatric RP2D	Dose escalation <sup>a</sup> /maximum 80% pediatric RP2D
Known in adults only	Dose confirmation/equivalent to adult RP2D	Dose escalation <sup>a</sup> /80% equivalent adult RP2D
Not known	Dose escalation <sup>a</sup> /per regulatory guidance for first-in-human study	Dose escalation <sup>a</sup> /per regulatory guidance for first-in-human study
Novel-Novel Combination		
Pediatric data available for both agents	Dose confirmation/pediatric RP2D of both agents	Dose escalation (two drugs) <sup>b</sup> /maximum 80% pediatric RP2D of both agents
One drug first-in-child <sup>c</sup> /one with pediatric data	Dose escalation (two drugs) <sup>b</sup> /pediatric RP2D of one agent and equivalent to adult RP2D for second agent	Dose escalation (two drugs) <sup>b</sup> /maximum 80% pediatric RP2D of one agent and 80% equivalent adult RP2D for second agent
Both drugs are first-in-child, <sup>c</sup> combination has not been evaluated in adults	Dose escalation (two drugs) <sup>b</sup> /80% equivalent adult RP2D for both agents	Dose escalation (two drugs) <sup>b</sup> /80% equivalent adult RP2D for both agents
Both drugs are first-in-child, <sup>c</sup> one drug with known adult PK, safety profile, and RP2D, and one drug with no knowledge of PK, safety profile and RP2D in adults	Dose escalation (two drugs) <sup>b</sup> /80% equivalent adult RP2D for first agent and follow regulatory guidance for first-in-human dosing for second agent	Dose escalation (two drugs) <sup>b</sup> /80% equivalent adult RP2D for first agent and follow regulatory guidance for first-in-human dosing for second agent

Abbreviations: CRM, continual reassessment method; DLT, dose-limiting toxicity; PK, pharmacokinetic; RP2D, recommended phase II dose.

<sup>a</sup>Dose escalation: escalation using a design to escalate one drug, for example, rolling six or CRM, depending on number of dose levels and targeted DLT rate.

<sup>b</sup>Dose escalation (two drugs): using a design to escalate two drugs, or rolling six if few and well-ordered combined dose levels, or partial ordering CRM, for unknown order.


<sup>c</sup>Limited monotherapy evaluation of the agent, before proceeding to combination.

Therapeutic intent is also enhanced in the context of combination studies of existing plus novel drugs if there is benefit with existing drug(s) alone. Randomized evaluation of a new agent plus standard therapy versus standard therapy is the most effective approach to isolate the effect and toxicity of the novel agent.<sup>36</sup> Early-phase platform studies,<sup>24-28</sup> where arms of different drugs can be evaluated, provide an efficient way for combinations to be evaluated for efficacy in relatively small patient populations and dropped rapidly if there is no early signal. Continual dialogue is required to challenge the perception that a phase I study has no realistic potential for benefit.<sup>37,38</sup> Early-phase testing must be designed with an eye toward where the combination might ultimately fit into existing treatment paradigms for newly diagnosed patients.<sup>10</sup>

As with all pediatric clinical trials, incorporating translational correlative research is a crucial element of early-phase trials, so that knowledge can be increased to guide future evaluation of more biologically rational combination regimens. Moreover, this approach will facilitate the detailed retrospective molecular analyses of responders and nonresponders to generate a revised or new hypothesis.

### Rationale for Combinations

Selection of combinations with compelling biological and clinical rationale for evaluation in children is essential, given the rarity of pediatric cancers and the mismatch between the immense numbers of combinations that are available for testing compared with the number of clinical trials that can be conducted. Prioritization of agents should be based on knowledge of tumor biology, molecular drivers of disease, a drug's mechanism of action, robust activity of the combination in relevant in vivo preclinical models that exceeds that of the component agents used alone, and therapeutic unmet needs.<sup>10</sup> Another important factor is the single-agent activity of the drugs used in the combination, as it is uncommon for meaningful clinical benefit to be observed for combinations in which an agent lacking evidence of single-agent activity is evaluated.<sup>4,39,40</sup> Recent advances from positive pediatric phase III trials highlight the importance of the activity of the agent added to standard-of-care regimens, as illustrated by rituximab for non-Hodgkin lymphoma,<sup>41</sup> brentuximab vedotin for high-risk Hodgkin lymphoma,<sup>42</sup> arsenic trioxide for acute promyelocytic leukemia,<sup>43</sup> blinatumomab for



**FIG 1.** Spectrum of designs and starting dose for pediatric combination trials. The design depends on the amount of known existing data relating to the drug and the target/entity in pediatrics and in adults, expectations for interactions or overlapping toxicities, and the number of drugs for which dose and schedule will be explored. At one end, there are second- or third-in-class products where there are pediatric data on the class and the emphasis is on dose confirmation. In the middle of the spectrum, only one drug is escalated for which there is some information from trials in adults, but some potential safety concerns or expected drug interactions—here, dose finding is required but could potentially start at the adult recommended dose for the same combination with planned escalation or de-escalation using an approach such as a rolling six design if the number of dose levels is smaller (only 2-3.) At the other end of the spectrum, there are combinations of novel-novel agents studied where there is no experience in adults and more than one drug is to be escalated or de-escalated; in this case, a partial ordering CRM approach is appropriate starting at a lower dose than adult equivalent RP2D. CRM, continual reassessment method; RP2D, recommended phase II dose.

B-cell acute lymphoblastic leukemia (ALL),<sup>44,45</sup> nelarabine for T-ALL,<sup>46</sup> and imatinib<sup>47</sup>/dasatinib<sup>48</sup> for Philadelphia chromosome-positive ALL and dinutuximab with chemotherapy for neuroblastoma.<sup>49</sup>

Evidence generated nonclinically is of paramount importance with the objective that the activity of the combination is at least additive or synergistic. Although synergy observed in preclinical studies may highlight combinations of potential interest, it is important to consider that the synergy observed for cancer cell lines *in vitro* may also apply to one or more critical normal tissues when combinations are tested in patients and translate into toxicity, with the result that there is little or no therapeutic window for the combinations. For this reason, *in vivo* studies with appropriate controls are required. An example is O<sup>6</sup>-benzylguanine plus nitrosoureas for high-grade gliomas. Remarkable preclinical synergy was observed for O<sup>6</sup>-benzylguanine plus nitrosourea combinations,<sup>50</sup> but in patients, the synergistic effect also applied to normal hematopoietic cells leading to excessive myelosuppression that required reduced doses of nitrosourea when biologically relevant doses of O<sup>6</sup>-benzylguanine were administered.<sup>51</sup> A phase III trial comparing O<sup>6</sup>-benzylguanine plus reduced-dose bischloronitrosourea, carmustine (BCNU) to full-dose BCNU for adults with high-grade glioma was stopped early for futility.<sup>52</sup> Other examples of preclinical synergy with excessive clinical toxicity are the combination of CHK1 inhibitors with gemcitabine,<sup>53</sup> MEK inhibitors with pan-HER inhibitors,<sup>54-57</sup> imatinib/dasatinib with high-dose chemotherapy,<sup>58</sup> and crizotinib with vinblastine in anaplastic large-cell lymphoma.<sup>59</sup>

The extent and depth of the preclinical studies required for support of combinations depend on the strength of the

underlying biological hypothesis. For example, if the target of an agent that is being incorporated into a combination is a well-defined oncogenic driver, then less evidence may be required. Conversely, in the majority of instances, when the agent lacks a predictive biomarker of response, robust preclinical evidence for a substantial combination effect is warranted before moving forward to clinical testing. Prioritization should be given to combinations with evidence of synthetic lethality, where inhibiting two targets together results in cell death, but inhibiting one target alone does not.<sup>60</sup> The ITCC-P4 and Pediatric Preclinical Testing Consortium<sup>12,61,62</sup> consensus on minimum preclinical testing requirements for the development of investigational therapies can facilitate combination strategies.

### Design Considerations

**Inclusion criteria.** Depending on preclinical and adult trial data, the pediatric dose-confirmation/finding phase may include an enriched selected population<sup>24,63</sup> or all-comers.<sup>64</sup> Another approach is to include all-comers in the dose-confirmation/finding phase and an enriched population for histology-/genomic-specific expansions to determine activity.<sup>65,66</sup> If there is biological rationale and potential benefit for the individual patient, such as non-biomarker-driven agents, all-comers may facilitate accrual and quickly ascertain a safe and adequate drug exposure dosing schedule. If preclinical or adult data suggest that antitumor activity is highly unlikely in an unselected population, eligibility criteria should be restricted to the relevant target population.<sup>63</sup> Biomarker-positive or histology-specific patients may be permitted to enter the study at any time at the best current estimate of a safe dose when there is no available slot in the main open cohort.<sup>67,68</sup> To maximally



use these data flexibly, statistical methods such as model-guided methods<sup>69</sup> (continual reassessment method [CRM]-type) may be used. When determining antitumor activity, the population should be restricted by disease or by biomarker to the target population for future clinical development or there should be partial enrichment to enroll a proportion of patients whose tumor has the target of interest. Patients who have prior exposure to single-agent therapy may be permitted, as this may reveal the benefit of the combination, by demonstrating response in a previously resistant population.<sup>70</sup>

**Defining the starting dose.** Confirmation of the adult body surface area (BSA)– or weight-adjusted RP2D should be the preferred strategy rather than dose finding. More conservative dose finding, starting at 20%-30% lower than the adult RP2D, may be warranted if there are safety concerns, a narrow therapeutic index, overlapping toxicities, or expected drug-drug interactions. The dose-confirmation approach will enable shorter studies.<sup>71–73</sup>

The sample size of the dose-confirmation cohort should enable the estimation of PK parameters and the determination of the recommended dose for the combination (RDC) for children.

**Dose and schedule finding.** In line with EMA guidelines,<sup>36</sup> studies should aim to identify the product(s) causing the observed adverse reactions to guide dose reductions in relation to observed toxicity. For example, if one agent is particularly likely to cause an observed adverse event (eg, rash), it should be de-escalated first. Generally, the novel product should be dose escalated/de-escalated first when a novel agent is combined with a known active agent or backbone. In addition, preclinical evidence of mechanism-based synergistic toxicity should be considered, for example, that seen with talazoparib and temozolomide.<sup>65</sup> Designs to de-escalate each component of the combination regimen if there is toxicity, or escalate if the exposure is less than occurring in adults or inadequate target inhibition, need to be pre-specified, so that trials are not halted unnecessarily.<sup>31,74</sup>

The concept of an *acceptable* toxicity should be considered, independently of its grade as per Common Terminology Criteria for Adverse Events. For example, reversible hematologic toxicity could be *acceptable*, in contrast to a permanent cardiac toxicity, which would be *unacceptable*. Class effects should be considered; for example, dose-limiting toxicity (DLT) definitions should exclude known class-related side effects easily manageable with supportive care. The concept of *tolerability* is also important, but potentially subjective, and might be measured as a quality-of-life metric. Increasing input from advocates and use of patient-reported outcomes is also encouraged, particularly for symptom-based toxicities for which concordance is poor between patient and clinician or caregiver reports.<sup>75–77</sup>

Preclinical evaluations for additivity and synergy can guide optimal exposures for combinations. However, optimal combination dose and schedule finding in patients may require simultaneous exploration of dose for each drug and multiple schedules. A CRM design for unknown toxicity ordering (partial ordering) is efficient in exploring dose combinations with as few patients as possible.<sup>78</sup> Dose-escalation strategies may include either cohorts that use alternate increases of each drug (or changes in schedule) or use of one drug in its standard single-agent dose and schedule and increase only the dose of the novel drug(s). Generally, if there are only two or three dose levels, then the rolling six design<sup>79</sup> can be acceptable. However, if there are more dose levels for the combination, a partial ordering CRM (POCRM) approach<sup>78</sup> (Table 3) is typically more accurate in identifying the combination dose and schedule and allows for tailoring which drug is escalated or de-escalated at completion of each cohort.<sup>80</sup> The POCRM can also be designed to avoid waiting lists, testing multiple doses and schedules in parallel.

**RDC.** It is not always possible to establish an optimal biological dose (eg, dose generating an adequate PD response without excessive toxicity) on the basis of PD data.<sup>81</sup> Despite a strong biological rationale and convincing preclinical work, generating exposure/PD response data in the target population may not be feasible if there are no relevant/validated biomarkers. Preclinical data and response data from clinical trials in adults may provide information to determine the RDC in pediatrics. Dose optimization and dose-finding rely on toxicity, tolerability,<sup>36</sup> and interpatient variability in exposure to target adult PK exposure with therapeutic drug monitoring whenever feasible.

Traditionally, the maximum tolerated dose (MTD) is defined on DLTs observed during cycle one of the dose-escalation phase, but the RDC should incorporate all information (eg, severe or chronic cumulative toxicity after cycle 1, dose modifications, PD and PK data, and toxicities that have significant impact on quality of life) since repeated dose reductions at cycles  $\geq 2$  are often because of chronic toxicity/intolerability that are not accounted in the definition of the MTD.<sup>82</sup> Dose optimization might also enable inpatient dose escalation (after achieving steady-state drug exposure or completion of two cycles and response evaluation) in patients who tolerate drugs and when therapeutic drug monitoring suggests a higher dose would be preferable.<sup>83,84</sup>

It is highly important to characterize doses and schedules of molecularly targeted therapy before initiating registration trials, as has been highlighted by Project Optimus of the US Food and Drug Administration (FDA).<sup>85</sup> An inadequately characterized dose and schedule of one or more combination agents may lead to more toxicity without additional efficacy, resulting in unwanted consequences, for example, persistent or irreversible toxicities and

inappropriate discontinuation of a potentially effective medicinal product.<sup>86</sup> Given the size of clinical trials needed to reliably optimize dose and schedule, this optimization generally needs to occur in adult cancer populations with extrapolation of the optimal dosage- and exposure-response relationships for efficacy and toxicity to pediatric patients.<sup>22</sup>

**Designs of trials with an initial monotherapy phase.** It is proposed that if a product is included in the combination where there are no previous pediatric data, a limited monotherapy evaluation, including an appropriate single-agent window, is included before proceeding to combination to better characterize dose, PK, toxicity, and, in some cases, single-agent activity. The starting dose for the monotherapy component should, in the absence of agent-specific toxicity, pharmacologic considerations, or a narrow therapeutic index, be 100% of the BSA-adjusted adult RP2D.<sup>9,21</sup> Designs should allow for transition from monotherapy to combination therapy in the same patient as soon as possible (after one or two courses) unless substantial single-agent activity is observed. The need to determine efficacy of monotherapy will depend upon whether its preclinical mechanism of action is only to enhance the activity of other agents in the combination, or it is active on its own, with the caveat that there are few examples of successful development of agents without single-agent activity that are used only to enhance the activity of other agents. The minimum possible number of patients should receive monotherapy<sup>87,88</sup> unless there is good evidence of single-agent activity and lack of evolving resistance to single-agent therapy.

**Summary of approach for selection of starting dose and dose-finding designs.** Table 3 and Figure 1 illustrate potential scenarios for early-phase combination trials depending upon a range of agent characteristics.

An FDA guidance on the codevelopment of two or more new investigational drugs for use in combination<sup>89</sup> is relevant to the developmental and regulatory pathways of novel-novel combinations in children, where there are no known pediatric data for at least one agent. This guidance also emphasizes the crucial importance of determining the contribution of each individual new investigational drug.

**Evaluation of antitumor activity in early-phase combination trials.** Randomized evaluation of a new agent plus standard therapy versus standard therapy is most effective to isolate the effect of the addition of the novel agent in a combination.<sup>36,71</sup> An underpowered randomization is considered acceptable and already agreed by the EMA.<sup>22,90</sup> Crossover from standard to combination regimen after progression of disease may be allowed.<sup>91</sup> This approach provides more robust evidence to identify promising regimens to take forward to later-stage trials and reduces the confounding effects of trial outcomes with unknown and uncontrollable trial effects such as patient selection, prior

treatment, age, sex, comorbidities, referral bias, and differences in supportive care,<sup>72</sup> compared with single-arm phase II trials. Relatively small, randomized expansion phases, randomized selection, or screening designs<sup>92,93</sup> can be very valuable in screening for activity of a novel agent added to standard therapy. Novel designs (such as Bayesian or two-stage minimax Jung designs)<sup>94,95</sup> can be used to minimize the sample size to 25-35 patients per cohort depending on the objectives and assumptions used in sample size determination. In this setting, controlling type I error (false positive) is less relevant than controlling type II error (false negative), as the goal of such trials is to ensure that if one regimen is superior, then there is a high probability that it will be selected. Pick-the-winner phase II randomized trial designs are another approach.<sup>96</sup> Randomization of patients two to one to receive the arm combined with the innovative agent versus standard of care, respectively, could be considered to accelerate accrual if patients are more willing/inclined to enroll. However, this approach might lower the power or increase the total sample size to maintain the same power<sup>97</sup> and should only be used if the activity of the investigational agent is expected to be high. The success or failure criteria generally are defined by clinically acceptable response rate or progression-free survival<sup>98</sup> that would lead to further evaluation of the drug. Intercontinental studies are required to recruit sufficient numbers of patients in studies with low incidence.

Evaluating activity using Ensign (3-stage design allowing for two interim analyses implemented)<sup>99</sup> or Simon's two-stage design<sup>100</sup> via a single-arm trial using robust historical control or population known to be resistant to the single agent has several disadvantages, particularly in the absence of meaningful control data.

Patients in the dose-confirmation portion of the study can be included in the expansion cohort if they received the pediatric RDC and have disease status appropriate for assessment of the response endpoint. All responses and nonresponses (even those observed at lower dose level) should be reported, and prolonged disease stabilizations in some instances may be relevant.

**Existing pediatric combination early-phase trials.** From a total of 287 trials including children in the ClinicalTrials.gov database, examples of published or presented pediatric combination early-phase trials are shown in Table 4.<sup>110</sup>

The phase I study of regorafenib in combination with vincristine and irinotecan was an amendment to single-agent regorafenib trial (ITCC-047). The combination used sequential dosing, had liberal DLT definitions,<sup>70</sup> and moved rapidly to a second-line treatment in rhabdomyosarcoma (compared with standard of care) in a platform trial (FaR-RMS).<sup>111</sup>

The phase I/II study lenvatinib with etoposide plus ifosfamide (ITCC-050) included a combination dose-finding phase and a combination expansion in patients with osteosarcoma.<sup>101,102</sup>

**TABLE 4.** Selected Published or Presented Pediatric Combination Early-Phase Trials Reviewed to Identify Key Themes in Combination Trial Design

Trial	Type of Study	Known PK and Safety of Novel Agent in Pediatrics	Adult Combination Data Available	Design	Outcome	Age of Eligibility	Disease	DLT Definition	Drug-Drug Interaction	RDC
Regorafenib + VI <sup>70</sup>	1	Yes	No	Rolling six dose finding; sequential dosing as first de-escalation; studied only two dose levels	RDC and preliminary activity established	Six months to younger than 18 years; different doses of regorafenib for very young children; suspension formulation available	All-comer solid tumors, but ≥50% required to have rhabdomyosarcoma	Liberal DLT definitions; allowance for substantial individualized dose modifications	CYP3A4 UGT1A9	Regorafenib at 100% RP2D: 82 mg/m <sup>2</sup> once every day combined sequentially with standard-dose VI
Lenvatinib + etoposide and ifosfamide <sup>101,102</sup>	1	Yes	No	Rolling six dose-finding phase; lenvatinib 80% of single-agent RP2D; combination expansion	RDC and preliminary activity established	2-25 years; no suspension available	Osteosarcoma	Standard	No	Lenvatinib 14 mg/m <sup>2</sup> (cap 24 mg) once daily; etoposide 100 mg/m <sup>2</sup> and ifosfamide 3,000 mg/m <sup>2</sup> days 1-3
Pazopanib + IT <sup>103</sup>	1	Yes	No	3 + 3 dose finding; pazopanib at 77% single-agent RP2D; no sequential dosing	RDC not determined because of DLT; class-specific; overlapping toxicity	6-21 years; no suspension available	All-comer sarcoma; difficult to decipher an efficacy signal	Strict DLT definitions for expected side effects (diarrhea, neutropenia, and ALT/AST). Many might not have been called DLT in regorafenib study	CYP3A4	Not determined even when de-escalated to 50% MTD doses of pazopanib and irinotecan
Alisertib + IT <sup>104</sup>	1	Yes	No	Rolling six dose-finding; alisertib at 56% single-agent MTD with standard IT	RDC and preliminary activity established	1-30 years	Neuroblastoma	Standard; amendment required to add myeloid growth factor	No	Alisertib at 75% single-agent MTD: 60 mg/m <sup>2</sup> with standard IT
Temsirolimus or dinutuximab + IT <sup>105</sup>	1	Yes	No	Dose confirmation/safety run-in; randomized phase II selection design	Confirmed tolerability of both regimens; showed higher response rate in chemoimmunotherapy arm, promoting that combination for further development	No age restriction	Neuroblastoma	Not specified, although unacceptable toxicity monitoring rule included	No	Confirmed tolerability of full-dose dinutuximab with standard doses of IT
Vorinostat as a radiation sensitizer with 131I-MIBG <sup>106</sup>	1	Yes	No	3 + 3 design; alternating dose escalation of vorinostat and MIBG; six dose levels	RDC and preliminary activity established	2-30 years	Neuroblastoma	Standard	No	Vorinostat at 180 mg/m <sup>2</sup> once every day with 18 mCi/kg MIBG
Venetoclax + TC <sup>86</sup>	2	No	No	Venetoclax monotherapy to confirm PK at equivalent dose to adult RP2D; separate combination dose finding with appropriate backbones in leukemias and solid tumors (TC); cohort expansions in combination	RDC could not be determined for continuous venetoclax in solid tumors with TC because of cytopenias; amended to include discontinuous schedule	Initially < 18 years; suspension available; TC combo cohort <25	ALL, AML, NHL All-comer solid tumors, with expansion in neuroblastoma	Standard	No	Determination of RDC for leukemias with continuous and solid tumors with discontinuous schedule (trial ongoing)

(continued on following page)



**TABLE 4.** Selected Published or Presented Pediatric Combination Early-Phase Trials Reviewed to Identify Key Themes in Combination Trial Design (continued)

Trial	Type of Study	Known PK and Safety of Novel Agent in Pediatrics	Adult Combination Data Available	Design	Outcome	Age of Eligibility	Disease	DLT Definition	Drug-Drug Interaction	RDC
Talazoparib + temozolomide <sup>65</sup>	3	No	No	3 + 3 design; started with 80% of adult MTD of talazoparib and escalated talazoparib before escalating temozolomide dose, which started at 40% of RP2D; six dose levels; PK and expansion cohort at the RP2D	RDC determined; synergistic toxicity, particularly neutropenia and thrombocytopenia; no objective responses in Ewing despite achieving talazoparib exposure active in adults	1-21 years for phase I; <30 years for phase II	All-comer solid tumors, with expansion in Ewing sarcoma with EWS-ETS fusions	Standard	Temozolomide Cmax increased with increasing doses of talozoparib	Talazoparib 600 µg/m <sup>2</sup> twice a day on day 1 and 600 µg/m <sup>2</sup> once every day days 2-6 (maximum 1,000 µg) and temozolomide 30 mg/m <sup>2</sup> once every day days 2-6
Dabrafenib and trametinib <sup>63</sup>	3	No	Yes (melanoma)	Seamless trial design. Part 1/2: single-agent trametinib escalation/expansions. Part 3: combination dose finding with trametinib at RP2D and limited dose escalation of dabrafenib in biomarker selected patients naive to MAPK pathway-targeted therapy. Part 4: histology (LGG) and biomarker cohort expansion	RDC determined and preliminary activity established in V600E mutant LGG	1-18 years Suspension formulation available for both agents	BRAF V600E mutant tumors, expansion in V600E mutant LGG and LCH	Not available	Not reported/not found	Trametinib 0.025 mg/kg once every day + dabrafenib 5.25 mg/kg once every day (<12 years) or 4.5 mg/kg once every day (≥12 years) orally continuously
Vorinostat +13 cis retinoic acid <sup>107</sup>	3	Yes	No	Seamless trial design. Single-agent vorinostat studied, then dose confirmation in combination with CisRA; only two dose levels studied: The second DL was a schedule de-escalation of vorinostat (four times per week v daily)	RDC determined and signal of efficacy in neuroblastoma	12 months-21 years	All-comer solid tumors; with combination in neuroblastoma, medulloblastoma, CNS PNET, or ATRT	Standard	Not reported No data on CisRA PK	13-CisRA 80 mg/m <sup>2</sup> /dose twice a day + vorinostat 180 mg/m <sup>2</sup> once every day, four times per week
Durvalumab ± tremelimumab <sup>108</sup>	4	No (but, yes using analogous agents)	Yes	Dose finding: cycle 1 durvalumab monotherapy; cycles 2-5 durvalumab/tremelimumab combination; cycle 6 + durvalumab monotherapy Dose expansion: cycles 1-4 combination and then durvalumab monotherapy	Trial ongoing	Younger than 18 years	Non-CNS solid tumors or lymphoma	Not available	Not anticipated	Ongoing trial

(continued on following page)

**TABLE 4.** Selected Published or Presented Pediatric Combination Early-Phase Trials Reviewed to Identify Key Themes in Combination Trial Design (continued)

Trial	Type of Study	Known PK and Safety of Novel Agent in Pediatrics	Adult Combination Data Available	Design	Outcome	Age of Eligibility	Disease	DLT Definition	Drug-Drug Interaction	RDC
Cixutumumab (IMC-A12) + temsirolimus (CCI-779) <sup>61</sup>	5	Yes	Yes	Modified 3 + 3 design; four dose levels, which included two dose reductions and a subsequent intermediate dose escalation	RDC determined but children unexpectedly tolerated the combo less well than adults because of severe mucositis; temsirolimus decreased to nearly 50% single-agent MTD (and 50% adult RDC)	12 months-21 years	All-comer solid tumors; separate sequential phase II	Standard	Overlapping toxicity (vertical pathway inhibition)	Cixutumumab 6 mg/kg + and temsirolimus 8 mg/m <sup>2</sup> weekly; strong PK/PD to validate dose/target inhibition
Lenvatinib + everolimus <sup>109</sup>	5	Yes	Yes (renal cell carcinoma)	Rolling 6 design; dose confirmation of adult RDC; DL-1 for dose de-escalation of lenvatinib only; planned escalations if needed; 3 planned expansions.	RDC determined; 2/3 DLTs in DL1 (one overturned by DSMC); de-escalated to DL-1 with 0/5 DLTs, then re-escalated to DL1; total 2/12 DLTs in DL1	2-18 years No suspension available	All-comer solid tumors; expansions in Ewing, HGG, and rhabdomyosarcoma	Standard	Not found	Lenvatinib 11 mg/m <sup>2</sup> once every day (cap 14 mg) + everolimus 3 mg/m <sup>2</sup> once every day (cap 5 mg) continuously
Ribociclib + everolimus <sup>24</sup>	5	Yes	Yes	Dose escalation using continuous reassessment method targeting a dose associated with 25% risk of DLT; 3 dose levels: ribo 25%/eve 50%; ribo 50%/eve 50%; ribo 50%/eve 75% (alternating dose escalation)	RDC was defined as DL2 (after DLTs occurring in DL3, and DL2 expanded)	Younger than 18 years	Biomarker-selected patients with activating alterations in CDK4/6 pathway and/or PI3K/AKT/mTOR pathway (eg, PIK3CA, TSC mutations, and loss of PTEN)	Standard	CYP3A4 Study showed ribociclib coadministration inhibited clearance of everolimus, increasing its exposure	Ribociclib 175 mg/m <sup>2</sup> once every day + everolimus 2.5 mg/m <sup>2</sup> once every day

NOTE. Type of study: standard of care (two or three drugs) and new drug (known PK, RP2D, and safety profile in pediatrics); standard of care (two or three drugs) and new drug (PK, RP2D, and safety profile not known in pediatrics); one innovative drug with no knowledge of PK, safety profile, and RP2D, and a drug with known PK, RP2D, safety profile; two innovative drugs with no knowledge of PK, safety profile, and RP2D, and two products, both with known pediatric PK, RP2D, and safety profiles.

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATRT, atypical teratoid rhabdoid tumor; CNS, central nervous system; DLT, dose-limiting toxicity; EWS-ETS, EWS gene-ETS transcription factor; HGG, high-grade glioma; IT, irinotecan and temozolomide; LGG, low-grade glioma; MIBG, metaiodobenzylguanidine; MTD, maximum tolerated dose; NHL, non-Hodgkin's lymphoma; PK, pharmacokinetic; PNET, peripheral neuroectodermal tumor; RDC, recommended dose for the combination; RP2D, recommended phase II dose; TC, topotecan and cyclophosphamide; VI, vincristine and irinotecan.

**TABLE 5.** Key Principles for Early-Phase Combination Trials in Pediatric Oncology

Principle
Regulatory
Importance of early engagement of regulators in clinical development of agents for pediatric cancers, including a full clinical development pathway comprising the design of early- and late-phase combination trials for novel agents
The trial design needs to consider regulatory requirements (PIPs and initial pediatric study plans) for all drugs included in the combination trial, so that it is fit for filing—the data set that meets the expectations for inclusion in a regulatory package
Designs need to isolate the effects of novel agent (both toxicity and antitumor effects)
Purpose of the trial
A robust biological rationale for the combination and clinical pharmacology and pharmacodynamics for targeted agents are paramount to design novel combinations
Extrapolation from adults may aid the design of the pediatric combination trials, but some combinations may also be first studied in children
There should be therapeutic intent in the combinations evaluated with potential patient benefit. This includes thoughtful/appropriate patient selection even in early-phase trials and the avoidance of subtherapeutic doses or trials that have many dose levels, or treat many patients below a potentially beneficial treatment dose
There needs to be a strategy designed for the combination's ultimate subsequent role in frontline therapy
Specific PK/toxicity studies in the very young (eg, younger than 2 years) may be appropriate depending upon the ultimate target population
Trial design
The trial design for early evaluation of combinations should be as simple and short as possible, as long as it adequately addresses the question
The general principle for combination early-phase studies is that if possible, they should be dose- and schedule-confirmatory, rather than exploratory
Go/no-go decisions should be incorporated early in the development of the combination trial to identify lack of activity in expansion cohorts, for excess toxicity, or interactions during dose escalation/confirmation
If not previously evaluated as monotherapy, limited evaluation of monotherapy (one cycle or less for one cohort, if single-agent activity is predicted to be low) should be included in the same clinical trial/protocol as the combination
Depending upon the combination of interest, the trial design may prioritize exposure to one agent over the other agent(s) in the combination, while other designs may be guided solely by toxicity or other considerations. Generally, if a novel agent is being added to standard of care, the dose and schedule of the new product will be escalated/de-escalated, while the dose and schedule of the standard regimen remains constant at the known therapeutic exposure
In expansion cohorts or subsequent trials, randomized determination of the activity of a new agent when combined with known active agent(s) should be considered. Recruiting patients previously known to be resistant to one of the agents could be considered
Platform trials have a major role in this setting as they share molecular analysis, standardize data management and biological sampling, accelerate the introduction of new combination arms, facilitate joint analyses of two arms with common investigational agent and different backbone and specific tumor types, and operationally are more efficient

Abbreviations: PIP, paediatric investigation plan; PK, pharmacokinetic.

This trial was followed by the OLIE (ITCC-082) randomized study evaluating the combination of lenvatinib with ifosfamide and etoposide compared with ifosfamide and etoposide alone (in relapsed/refractory osteosarcoma<sup>112</sup>). This efficient design could have been further accelerated if the randomized comparison had been integrated into the initial protocol and followed the phase I/II component.

The dabrafenib and trametinib combination trial began with a single-agent cohort to determine the RP2D of trametinib. This led to a limited dose escalation of dabrafenib and trametinib, followed by an expansion of the combination in patients with *BRAF* V600-mutant low-grade glioma.<sup>63</sup> The combination was demonstrated to have a superior overall response rate and median progression-free survival when randomized against standard of care (carboplatin and vincristine) in pediatric low-grade gliomas.<sup>113</sup>

In conclusion, children and adolescents with cancer deserve early access to innovative drugs in clinical trials, and

those agents that are potentially beneficial need to be evaluated expeditiously. Clinical trials should maximize the potential for benefit in the greatest possible proportion of patients contributing to such trials. Combinations should be developed on the basis of mechanism of action, cancer biology, robust preclinical evaluation, and clinical activity for the agent when known (Table 5). We propose that optimally efficient early-phase combination trials combine dose-confirmation/finding and randomized expansion cohorts in the tumor or target of interest.

Very early discussion of trial designs with regulators is essential so that trials fulfill both scientific and regulatory purposes. Including parent advocates meaningfully in these early stages will help reveal potential points of confusion and misinformation, help shape strategies to increase recruitment and educate study participants, and help raise the likelihood of on-time completion of planned enrollment. Furthermore, this approach would allow

children with rare conditions available to participate in clinical trials to be evaluated in the most parsimonious way possible.

A fit-for-purpose approach to the design of early-phase pediatric combination trials will benefit all stakeholders, especially children and adolescents with cancer.

## AFFILIATIONS

- <sup>1</sup>Hospital Universitari Vall d'Hebron, Barcelona, Spain  
<sup>2</sup>Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA  
<sup>3</sup>Memorial Sloan Kettering Cancer Center, New York, NY  
<sup>4</sup>Solving Kids' Cancer UK, London, United Kingdom  
<sup>5</sup>Coalition Against Childhood Cancer (CAC2), Philadelphia, PA  
<sup>6</sup>Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy  
<sup>7</sup>Université Paris Cité, Paris, France  
<sup>8</sup>SIREDO Centre (Care, Innovation Research in Pediatric, Adolescent and Young Adults Oncology), Institut Curie, Paris, France  
<sup>9</sup>St Jude Children's Research Hospital, Memphis, TN  
<sup>10</sup>Children's Hospital Colorado, Aurora, CO  
<sup>11</sup>University of Colorado, Aurora, CO  
<sup>12</sup>Seattle Children's Hospital, Seattle, WA  
<sup>13</sup>Children's Oncology Group  
<sup>14</sup>Rina Zaizov Pediatric Hematology Oncology Division, Schneider Children's Medical Center of Israel, Petah Tikva, Israel  
<sup>15</sup>Hematological Malignancies Centre of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel  
<sup>16</sup>Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany  
<sup>17</sup>Division of Pediatric Neurooncology, DKFZ, KiTZ  
<sup>18</sup>Clinical Trial Unit and Childhood Brain Tumors, Heidelberg University Hospital, Heidelberg, Germany  
<sup>19</sup>Division of Pediatric Glioma Research, German Cancer Research Center (DKFZ), Heidelberg, Germany  
<sup>20</sup>Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom  
<sup>21</sup>NIHR Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, United Kingdom  
<sup>22</sup>Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands  
<sup>23</sup>Department of Pharmaceutical Sciences Utrecht University, Utrecht, the Netherlands  
<sup>24</sup>Rigshospitalet, Copenhagen, Denmark  
<sup>25</sup>U.S. Food and Drug Administration, Silver Spring, MA  
<sup>26</sup>National Cancer Institute, MA  
<sup>27</sup>University of Minnesota, MN  
<sup>28</sup>Innovative Therapies for Children with Cancer, Paris, France

<sup>29</sup>ACCELERATE, Brussels, Belgium

<sup>30</sup>Gustave Roussy Cancer Centre, Paris, France

<sup>31</sup>Department of Pediatric Oncology, Hematology, Erasmus MC, Sophia Children's Hospital, the Netherlands

<sup>32</sup>Institut Curie, Paris, France

## CORRESPONDING AUTHOR

Andrew D.J. Pearson, MBBS, MD, DCH, Innovative Therapies for Children with Cancer (ITCC) 114 rue Edouard Vaillant, 94805, Villejuif cedex, France; e-mail: andy1pearson@btinternet.com.

## DISCLAIMER

The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of, or reflecting the position of, the agencies or organizations with which the authors are affiliated.

## EQUAL CONTRIBUTION

L.M., S.G.D., J.G.B., and A.M. are joint first authors.

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI <https://doi.org/10.1200/JCO.22.02430>.

## AUTHOR CONTRIBUTIONS

**Conception and design:** Lucas Moreno, Steven G. DuBois, Julia Glade Bender, Audrey Mauguen, Xavier Paoletti, Alexia Iasonis, Andrew D.J. Pearson

**Provision of study materials or patients:** All authors

**Data analysis and interpretation:** All authors

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

## ACKNOWLEDGMENT

The authors very gratefully acknowledge Gynette Cook for preparation of the manuscript.

## REFERENCES

- Noom AM, Howlader N, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2015. Bethesda, MD, National Cancer Institute, 2018 [https://seer.cancer.gov/csr/1975\\_2015/](https://seer.cancer.gov/csr/1975_2015/)
- Williams AM, Liu Q, Bhakta N, et al: Rethinking success in pediatric oncology: Beyond 5-year survival. *J Clin Oncol* 39:2227-2231, 2021
- Yeh JM, Ward ZJ, Chaudhry A, et al: Life expectancy of adult survivors of childhood cancer over 3 decades. *JAMA Oncol* 6:350-357, 2020
- Foster J, Freidlin B, Korn EL, et al: Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity. *ESMO Open* 5:e000871, 2020
- Plana D, Palmer AC, Sorger PK: Independent drug action in combination therapy: Implications for precision oncology. *Cancer Discov* 12:606-624, 2022
- Frei E 3rd, Karon M, Levin RH, et al: The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. *Blood* 26:642-656, 1965
- Prowell TM, Theoret MR, Pazdur R: Seamless oncology-drug development. *N Engl J Med* 374:2001-2003, 2016
- Smith M, Bernstein M, Bleyer WA, et al: Conduct of Phase I trials in children with cancer. *J Clin Oncol* 16:966-978, 1998
- Moreno L, Pearson ADJ, Paoletti X, et al: Early phase clinical trials of anticancer agents in children and adolescents—An ITCC perspective. *Nat Rev Clin Oncol* 14:497-507, 2017
- Pearson AD, Herold R, Rousseau R, et al: Implementation of mechanism of action biology-driven early drug development for children with cancer. *Eur J Cancer* 62:124-131, 2016

11. Pearson ADJ, Pfister SM, Baruchel A, et al: From class waivers to precision medicine in paediatric oncology. *Lancet Oncol* 18:e394-e404, 2017
12. Vassal G, Houghton PJ, Pfister SM, et al: International consensus on minimum preclinical testing requirements for the development of innovative therapies for children and adolescents with cancer. *Mol Cancer Ther* 20:1462F-1468F, 2021
13. Neel DV, Shulman DS, DuBois SG: Timing of first-in-child trials of FDA-approved oncology drugs. *Eur J Cancer* 112:49-56, 2019
14. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on Medicinal Products for Paediatric Use and Amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance). <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32006R1901&qid=1685131056256>
15. European Medicines Agency: European Medicines Agency decision (CW/0001/2015) of 23 July 2015 on class waivers, in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council. [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Other/2015/07/WC500190385.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Other/2015/07/WC500190385.pdf)
16. US Congress: FDA Reauthorization Act of 2017. <https://www.congress.gov/115/plaws/publ52/PLAW-115publ52.pdf>
17. Vassal G, Rousseau R, Blanc P, et al: Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. *Eur J Cancer* 51:218-224, 2015
18. Pearson ADJ, Weiner SL, Adamson PC, et al: Accelerate—Five years accelerating cancer drug development for children and adolescents. *Eur J Cancer* 166:145-164, 2022
19. Deverka PA, Bangs R, Kreizenbeck K, et al: A new framework for patient engagement in cancer clinical trials cooperative group studies. *J Natl Cancer Inst* 110:553-559, 2018
20. Rossoni C, Bardet A, Georger B, et al: Sequential or combined designs for phase I/II clinical trials? A simulation study. *Clin Trials* 16:635-644, 2019
21. Paoletti X, Georger B, Doz F, et al: A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials. *Eur J Cancer* 49:2392-2402, 2013
22. European Medicines Agency: Reflection Paper on Extrapolation of Efficacy and Safety in Paediatric Medicine Development. [https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-e11a-pediatric-extrapolation-step-2b\\_en](https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-e11a-pediatric-extrapolation-step-2b_en)
23. The Adaptive Platform Trials Coalition: Adaptive platform trials: Definition, design, conduct and reporting considerations. *Nat Rev Drug Discov* 18:797-807, 2019
24. Bautista F, Paoletti X, Rubino J, et al: Phase I or II study of ribociclib in combination with topotecan-temozolomide or everolimus in children with advanced malignancies: Arms A and B of the AcSé-ESMART trial. *J Clin Oncol* 39:3546-3560, 2021
25. European proof-of-concept therapeutic stratification trial of molecular anomalies in relapsed or refractory tumors (ESMART)
26. Morscher RJ, Brard C, Berlanga P, et al: First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial. *Eur J Cancer* 157:268-277, 2021
27. Parsons DW, Janeway KA, Patton DR, et al: Actionable tumor alterations and treatment protocol enrollment of pediatric and young adult patients with refractory cancers in the national cancer institute-children's oncology group pediatric MATCH trial. *J Clin Oncol* 40:2224-2234, 2022
28. Eckstein OS, Allen CE, Williams PM, et al: Phase II study of selumetinib in children and young adults with tumors harboring activating mitogen-activated protein kinase pathway genetic alterations: Arm E of the NCI-COG pediatric MATCH trial. *J Clin Oncol* 40:2235-2245, 2022
29. Doz F, Gentet JC, Pein F, et al: Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: A SFOP study. *Br J Cancer* 84:604-610, 2001
30. Gore L, Trippett TM, Katzenstein HM, et al: A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors. *Clin Cancer Res* 19:3649-3658, 2013
31. Mossé YP, Lim MS, Voss SD, et al: Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: A children's oncology group phase 1 consortium study. *Lancet Oncol* 14:472-480, 2013
32. Mossé YP, Lipsitz E, Fox E, et al: Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of aurora kinase A: A children's oncology group phase I consortium study. *Clin Cancer Res* 18:6058-6064, 2012
33. Vassal G, Doz F, Frappaz D, et al: A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. *J Clin Oncol* 21:3844-3852, 2003
34. Pestana RC, Sen S, Hobbs BP, et al: Histology-agnostic drug development—Considering issues beyond the tissue. *Nat Rev Clin Oncol* 17:555-568, 2020
35. Laetsch TW, DuBois SG, Mascarenhas L, et al: Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: Phase 1 results from a multicentre, open-label, phase 1/2 study. *Lancet Oncol* 19:705-714, 2018
36. EMA Anticancer Guideline (EMA/CHMP/205/95 Rev.6). [https://www.ema.europa.eu/documents/scientific-guideline/draft-guideline-evaluation-anticancer-medicinal-products-man-revision-6\\_en.pdf](https://www.ema.europa.eu/documents/scientific-guideline/draft-guideline-evaluation-anticancer-medicinal-products-man-revision-6_en.pdf)
37. Miller FG, Joffe S: Benefit in phase 1 oncology trials: Therapeutic misconception or reasonable treatment option?. *Clin Trials* 5:617-623, 2008
38. Schupmann W, Li X, Wendler D: Do the potential medical benefits of phase 1 pediatric oncology trials justify the risks? Views of the United States public. *J Pediatr* 238:249-258.e3, 2021
39. Palmer AC, Sorger PK: Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. *Cell* 171:1678-1691.e13, 2017
40. Carlisle BG, Doussau A, Kimmelman J: Benefit, burden, and impact for a cohort of post-approval cancer combination trials. *Clin Trials* 17:18-29, 2020
41. Minard-Colin V, Auperin A, Pillon M, et al: Rituximab for high-risk, mature B-cell non-Hodgkin's lymphoma in children. *N Engl J Med* 382:2207-2219, 2020
42. Castellino SM, Pei Q, Parsons SK, et al: Brentuximab vedotin demonstrates superior event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the children's oncology group phase 3 study AHOD1331 (NCT 02166463). *ASCO Annu Meet*, 2022. Abstr #7504
43. Kutny MA, Alonzo TA, Abla O, et al: Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: A report from the children's oncology group AAML1331 trial. *JAMA Oncol* 8:79-87, 2022
44. Brown PA, Ji L, Xu X, et al: Effect of Postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: A randomized clinical trial. *JAMA* 325:833-842, 2021
45. Locatelli F, Zugmaier G, Rizzari C, et al: Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: A randomized clinical trial. *JAMA* 325:843-854, 2021
46. Dunsmore KP, Winter SS, Devidas M, et al: Children's oncology group AALL0434: A phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. *J Clin Oncol* 38:3282-3293, 2020
47. Schultz KR, Devidas M, Bowman WP, et al: Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: Results from children's oncology group study AALL0031. *Leukemia* 28:964-967, 2014



48. Shen S, Chen X, Cai J, et al: Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: A randomized clinical trial. *Clinical trial*. *JAMA Oncol* 6:358-366, 2020
49. Mody R, Naranjo A, Van Ryn C, et al: Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): An open-label, randomised, phase 2 trial. *Lancet Oncol* 18:946-957, 2017
50. Dolan ME, Mitchell RB, Mummert C, et al: Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. *Cancer Res* 51:3367-3372, 1991
51. Friedman HS, Pluda J, Quinn JA, et al: Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. *J Clin Oncol* 18:3522-3528, 2000
52. Blumenthal DT, Rankin C, Stelzer KJ, et al: A Phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. *Int J Clin Oncol* 20:650-658, 2015
53. Italiano A, Infante JR, Shapiro GI, et al: Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. *Ann Oncol* 29:1304-1311, 2018
54. Sun C, Hobor S, Bertotti A, et al: Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. *Cell Rep* 7:86-93, 2014
55. Huijberts SCFA, van Geel RMJM, van Brummelen EMJ, et al: Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. *Cancer Chemother Pharmacol* 85:917-930, 2020
56. Brummelen EM, Huijberts S, Herpen C, et al: Phase I study of afatinib and selumetinib in patients with KRAS-mutated colorectal, non-small cell lung, and pancreatic cancer. *Oncologist* 26:290-e545, 2021
57. van Geel RMJM, van Brummelen EMJ, Eskens FALM, et al: Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. *Br J Cancer* 122:1166-1174, 2020
58. Biondi A, Gandemer V, De Lorenzo P, et al: Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): A prospective, intergroup, open-label, single-arm clinical trial. *Lancet Haematol* 5:e641-e652, 2018
59. Knörr F, Schellekens KPJ, Schoot RA, et al: Combination Therapy with Crizotinib and Vinblastine for Relapsed or Refractory Pediatric ALK-Positive Anaplastic Large Cell Lymphoma. *Haematologica* 108:1442-1446, 2023
60. O'Neil NJ, Bailey ML, Hieter P: Synthetic lethality and cancer. *Nat Rev Genet* 18:613-623, 2017
61. Innovative Therapies for Children with Cancer—Pediatric Preclinical Proof-Of Concept Project. <https://www.itccp4.eu>
62. NCI-Funded Pediatric Preclinical Testing Consortium (PPTC). <http://www.ncipptc.org>
63. Georger B, Bouffet E, Whitlock JA, et al: Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results. *J Clin Oncol* 38:10506, 2020 (supp; abstr 10506)NCT02124772
64. Fouladi M, Perentesis JP, Wagner LM, et al: A phase I study of cixutumumab (IMC-A12) in combination with temsirolimus (CCI-779) in children with recurrent solid tumors: A children's oncology group phase I consortium report. *Clin Cancer Res* 21:1558-1565, 2015
65. Schafer ES, Rau RE, Berg SL, et al: Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including ewing sarcoma: A children's oncology group phase 1 consortium study (ADVL1411). *Pediatr Blood Cancer* 67:e28073, 2020
66. Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants with Solid Tumors (SCOOP). <https://clinicaltrials.gov/ct2/show/NCT04544995>
67. Study of the Bromodomain (BRD) and Extra-terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer. <https://clinicaltrials.gov/ct2/show/NCT03936465>
68. Desai AV, Robinson GW, Gauvain K, et al: Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1 or ALK aberrations (STARTRK-NG). *Neuro-Oncology* 24:1776-1789, 2022
69. O'Quigley J, Pepe M, Fisher L: Continual reassessment method: A practical design for phase 1 clinical trials in cancer. *Biometrics* 46:33-48, 1990
70. Casanova M, Bautista F, Campbell Hewson Q, et al: Phase I study of rogerafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors. *J Clin Oncol* 38:10507, 2020 (supp; abstr 10507)NCT02085148
71. Iasonos A, O'Quigley J: Randomised Phase 1 clinical trials in oncology. *Br J Cancer* 125:920-926, 2021
72. Stathis A, Iasonos A, Seymour JF, et al: Report of the 14th international conference on malignant lymphoma (ICML) closed Workshop on future design of clinical trials in lymphomas. *Clin Cancer Res* 24:2993-2998, 2018
73. Olmos D, Postel-Vinay S, Molife LR, et al: Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751, 871) in patients with sarcoma and ewing's sarcoma: A phase 1 expansion cohort study. *Lancet Oncol* 11:129-135, 2010
74. Foster JH, Voss SD, Hall DC, et al: Activity of crizotinib in patients with ALK-aberrant relapsed/refractory neuroblastoma: A children's oncology group study (ADVL0912). *Clin Cancer Res* 27:3543-3548, 2021
75. Ped-PRO-CTCAE/Ped-PRO-CTCAE [Caregiver]: Instrument & Form Builder. <https://healthcaredelivery.cancer.gov/pro-ctcae/instrument-ped.html>
76. Hinds PS, Pinheiro LC, McFatrach M, et al: Recommended scoring approach for the pediatric patient-reported outcomes version of the Common Terminology Criteria for Adverse Events. *Pediatr Blood Cancer* 69:e29452, 2022
77. Freyer DR, Lin L, Mack JW, et al: Lack of concordance in symptomatic adverse event reporting by children, clinicians, and caregivers: Implications for cancer clinical trials. *J Clin Oncol* 40:1623-1634, 2022
78. Wages NA, Conaway MR, O'Quigley J: Dose-finding design for multi-drug combinations. *Clin Trials* 8:380-389, 2011
79. Skolnik JM, Barrett JS, Jayaraman B, et al: Shortening the timeline of pediatric phase I trials: The rolling six design. *J Clin Oncol* 26:190-195, 2008
80. Saha PT, Fine JP, Ivanova A: Consistency of the CRM when the dose-toxicity curve is not monotone and its application to the POCRM. *Stat Med* 40:2073-2082, 2021
81. Fraisse J, Dinart D, Tosi D, et al: Optimal biological dose: A systematic review in cancer phase I clinical trials. *BMC Cancer* 21:60, 2021
82. Bautista F, Moreno L, Marshall L, et al: Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium. *Eur J Cancer* 86:275-284, 2017
83. Ratain MJ, Goldstein DA, Lichter AS: Interventional pharmacoeconomics—A new discipline for a cost-constrained environment. *JAMA Oncol* 5:1097-1098, 2019
84. Serritella AV, Strohbehn GW, Goldstein DA, et al: Interventional pharmacoeconomics: A novel mechanism for Unlocking value. *Clin Pharmacol Ther* 108:487-493, 2020
85. Project Optimus—Reforming the dose optimization and dose selection paradigm in oncology. [www.fda.gov/about-fda/oncology-center-excellence/project-optimus](http://www.fda.gov/about-fda/oncology-center-excellence/project-optimus)

86. Shah M, Rahman A, Theoret MR, et al: The drug-dosing conundrum in oncology—When less is more. *N Engl J Med* 385:1445-1447, 2021
87. Goldsmith KC, Verschuur A, Morgenstern DA, et al: The first report of pediatric patients with solid tumors treated with venetoclax. *J Clin Oncol* 38:10524, 2020. (supp; abstr 10524)
88. Place AE, Goldsmith K, Bourquin J-P, et al: Accelerating drug development in pediatric cancer: A novel phase I study design of venetoclax in relapsed/refractory malignancies. *Future Oncol* 14:2115-2129, 2018
89. Codevelopment of Two or More New Investigational Drugs for Use in Combination. <https://www.fda.gov/files/drugs/published/Codevelopment-of-Two-or-More-New-Investigational-Drugs-for-Use-in-Combination.pdf>
90. European Medicines Agency: European Medicines Agency decision P/0217/2021 of 9 June 2021 on the acceptance of a modification of an agreed paediatric investigation plan for venetoclax (Venclyxto), (EMA-002018-PIP02-16-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council. [https://www.ema.europa.eu/en/documents/pip-decision/p/0217/2021-ema-decision-9-june-2021-acceptance-modification-agreed-paediatric-investigation-plan\\_en.pdf](https://www.ema.europa.eu/en/documents/pip-decision/p/0217/2021-ema-decision-9-june-2021-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf)
91. A Study of LY3295668 Erbumine in Participants with Relapsed/Refractory Neuroblastoma. <https://clinicaltrials.gov/ct2/show/NCT04106219>
92. Rubinstein LV, Korn EL, Freidlin B, et al: Design issues of randomized phase II trials and a proposal for phase II screening trials. *J Clin Oncol* 23:7199-7206, 2005
93. Torres-Saavedra PA, Winter KA: An Overview of phase 2 clinical trial designs. *Int J Radiat Oncol\*Biophys* 112:22-29, 2022
94. Billingham L, Malotki K, Steven N: Research methods to change clinical practice for patients with rare cancers. *Lancet Oncol* 17:e70-e80, 2016
95. Jung SH: Randomized phase II trials with a prospective control. *Stat Med* 27:568-583, 2008
96. Mandrekar SJ, Sargent DJ: Pick the winner designs in phase II cancer clinical trials. *J Thorac Oncol* 1:5-6, 2006
97. Korn EL, Freidlin B: Outcome—Adaptive randomization: Is it useful?. *J Clin Oncol* 29:771-776, 2011
98. Del Paggio JC, Berry JS, Hopman WM, et al: Evolution of the randomized clinical trial in the era of precision oncology. *JAMA Oncol* 7:728-734, 2021
99. Ensign LG, Gehan EA, Kamen DS, et al: An optimal three-stage design for phase II clinical trials. *Stat Med* 13:1727-1736, 1994
100. Simon R, Christian MC, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. *JNCI J Natl Cancer Inst* 89:1138-1147, 1997
101. Gaspar N, Venkatramani R, Hecker-Nolting S, et al: Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): A multicentre, open-label, multicohort, phase 1/2 study. *Lancet Oncol* 22:1312-1321, 2021
102. Gaspar N, Campbell-Hewson Q, Gallego Melcon S, et al: Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050). *ESMO Open* 6:100250, 2021
103. Vo KT, Michlitsch JG, Shah AT, et al: Phase I trial of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma. *J Clin Oncol* 38:10526, 2020 (supp 6; abstr 10526)NCT03139331
104. DuBois SG, Marachelian A, Fox E, et al: Phase I study of the aurora A kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: A NANT (new approaches to neuroblastoma therapy) trial. *J Clin Oncol* 34:1368-1375, 2016
105. Mody R, Naranjo A, Van Ryn C, et al: Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): An open-label, randomised, phase 2 trial. *Lancet Oncol* 18:946-957, 2017
106. DuBois SG, Groshen S, Park JR, et al: Phase I study of vorinostat as a radiation sensitizer with 131I-metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma. *Clin Cancer Res* 21:2715-2721, 2015
107. Fouladi M, Park JR, Stewart CF, et al: Pediatric phase I trial and pharmacokinetic study of vorinostat: A children's oncology group phase I consortium report. *J Clin Oncol* 28:3623-3629, 2010
108. Durvalumab and Tremelimumab for Pediatric Malignancies. <https://clinicaltrials.gov/ct2/show/NCT03837899>
109. Dela Cruz FS, DuBois SG, Fox E, et al: A phase I/II study of lenvatinib (LEN) plus everolimus (EVE) in recurrent and refractory pediatric solid tumors, including CNS tumors. *J Clin Oncol* 38:10527, 2020 (supp 6; abstr 10527)
110. ClinicalTrials.gov. <https://clinicaltrials.gov/>
111. FaR-RMS: An Overarching Study for Children and Adults with Frontline and Relapsed RhabdoMyoSarcoma (FaR-RMS). <https://clinicaltrials.gov/ct2/show/NCT04625907>
112. A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide with or without Lenvatinib in Children, Adolescents and Young Adults with Relapsed and Refractory Osteosarcoma. <https://clinicaltrials.gov/ct2/show/NCT04154189>
113. Bouffet E, Hansford J, Garre ML, et al: Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600-mutant pediatric low-grade glioma (pLGG). *J Clin Oncol*:40, 2022



## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

## Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/jco/authors/author-center](http://ascopubs.org/jco/authors/author-center).

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](http://Open Payments)).

**Lucas Moreno**

**Honoraria:** Bayer (Inst), EUSA Pharma (Inst)

**Consulting or Advisory Role:** Shionogi (Inst), Novartis (Inst), Boehringer Ingelheim (Inst), Norgine (Inst)

**Patents, Royalties, Other Intellectual Property:** Member of SIOOPEN Executive Committee, SIOOPEN receives royalties for the sales of dinutuximab beta (Inst)

**Uncompensated Relationships:** Ymabs Therapeutics Inc (Inst)

**Steven G. DuBois**

**Consulting or Advisory Role:** Bayer, Amgen, Jazz Pharmaceuticals

**Research Funding:** Merck (Inst), Roche/Genentech (Inst), Lilly (Inst), Curis (Inst), Loxo (Inst), BMS (Inst), Eisai (Inst), Pfizer (Inst), Turning Point Therapeutics (Inst), Bayer (Inst), Salaris Pharmaceuticals (Inst)

**Travel, Accommodations, Expenses:** Roche/Genentech, Salaris Pharmaceuticals

**Uncompensated Relationships:** Ymabs Therapeutics Inc

**Julia Glade Bender**

**Consulting or Advisory Role:** Jazz Pharmaceuticals

**Research Funding:** Eisai (Inst), Lilly (Inst), Loxo (Inst), Roche/Genentech (Inst), Bayer (Inst), Jazz Pharmaceuticals (Inst)

**Patents, Royalties, Other Intellectual Property:** Patent on a T lymphoblastic lymphoma cell line, CUTLL1

**Travel, Accommodations, Expenses:** Amgen (Inst)

**Uncompensated Relationships:** SpringWorks Therapeutics, Bristol Myers Squibb, Merck, Eisai, Pfizer

**Open Payments Link:** <https://openpaymentsdata.cms.gov/physician/708514>

**Audrey Mauguen**

**Research Funding:** ImaginAb (Inst), Amgen (Inst)

**Patents, Royalties, Other Intellectual Property:** coinventor of provisional patent Number 63/193,700, filed on 5/27/21; conversion deadline: 5/27/22; named "Soothsayer," filed by Office of Technology Development, MSKCC

**Michela Casanova**

**Consulting or Advisory Role:** Bayer, BMS, AstraZeneca, Servier, Pfizer

**François Doz**

**Consulting or Advisory Role:** ROCHE GENNENTECH (Inst), SERVIER (Inst), Ipsen (Inst), Novartis (Inst)

**Research Funding:** ONXEO (Inst)

**Travel, Accommodations, Expenses:** Bayer

**Lia Gore**

**Stock and Other Ownership Interests:** Amgen, Sanofi, Mirati Therapeutics, OnKure

**Consulting or Advisory Role:** Novartis, Amgen, Roche/Genentech, Syndax, OnKure, Janssen Oncology, Pfizer

**Patents, Royalties, Other Intellectual Property:** Patent held for diagnostic discovery and treatment response methodology tools in the use of MR spectroscopy for leukemia

**Uncompensated Relationships:** Kestrel Therapeutics

**Douglas S. Hawkins**

**Research Funding:** Bayer (Inst), Lilly (Inst), Jazz Pharmaceuticals (Inst), Pfizer (Inst)

**Shai Izraeli**

**Honoraria:** Foundation Medicine

**Speakers' Bureau:** Oncotest/Rhenium

**David T.W. Jones**

**Patents, Royalties, Other Intellectual Property:** Patent WO 2013075237 A1, titled "Mutations of histone proteins associated with proliferative disorders," Patent WO2016142533A1, titled "DNA methylation-based method for classifying tumor species"

**Pamela R. Kearns**

**Consulting or Advisory Role:** Bristol Myers Squibb, Bayer, AstraZeneca

**Research Funding:** Pfizer (Inst), Bayer (Inst)

**Karsten Nysom**

**Honoraria:** Y-mAbs Therapeutics

**Consulting or Advisory Role:** Bayer, EUSA Pharma, Ymabs Therapeutics Inc, Lilly

**Stefan Pfister**

**Stock and Other Ownership Interests:** Heidelberg Epignostix

**Consulting or Advisory Role:** BioSkrbyb

**Research Funding:** Lilly (Inst), Bayer (Inst), Roche (Inst), PharmaMar (Inst), Pfizer (Inst), AstraZeneca (Inst), Janssen & Janssen (Inst), Servier (Inst), Sanofi (Inst), Amgen (Inst)

**Patents, Royalties, Other Intellectual Property:** patent on using DNA methylation profiling for tumor classification, patent using nanopore sequencing for rapid tumor diagnostics

**Gilles Vassal**

**Consulting or Advisory Role:** Bayer, Roche/Genentech, AstraZeneca, Bristol Myers Squibb, Lilly, Novartis, Pfizer, Hutchinson-Medi Pharma, Pyramid

**Travel, Accommodations, Expenses:** Bristol Myers Squibb, Roche, Bayer

**Christian Michel Zwaan**

**Consulting or Advisory Role:** Takeda (Inst), Pfizer (Inst), AbbVie (Inst), Jazz Pharmaceuticals (Inst), Incyte (Inst), Novartis (Inst), Kura Oncology (Inst)

**Research Funding:** Takeda (Inst), AbbVie/Genentech (Inst), Pfizer (Inst), Jazz Pharmaceuticals (Inst), Kura Oncology (Inst), Daiichi Sankyo (Inst)

**Xavier Paoletti**

**Honoraria:** MSD Oncology

**Consulting or Advisory Role:** MSD Oncology, Daiichi Sankyo

**Speakers' Bureau:** Ipsen

**Alexia Iasonos**

This author is a deputy editor for *Journal of Clinical Oncology*. Journal policy recused the author from having any role in the peer review of this manuscript

**Stock and Other Ownership Interests:** Bristol Myers Squibb/Sanofi

**Consulting or Advisory Role:** Intelligencia, Mirati Therapeutics

**Andrew D.J. Pearson**

**Honoraria:** Lilly, Amgen, Developmental Therapeutics Consortium, Norgine

**Consulting or Advisory Role:** Lilly, Amgen, Developmental Therapeutics Consortium, Norgine

No other potential conflicts of interest were reported.